Revenue
2022
2023
2024
2025
Envoy Medical, Inc. (COCH)
Price$0.7100Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $241,000 | $225,000 | $316,000 | $237,000 | — |
| Gross profit | −$633,000 | −$517,000 | −$473,000 | −$261,000 | — |
| Gross margin | −262.66% | −229.78% | −149.68% | −110.13% | — |
| Research & development | $12.5M | $10.2M | $9.0M | $5.0M | — |
| Operating expenses | $22.5M | $19.5M | $18.7M | $8.9M | $5.2M |
| Operating income | −$22.3M | −$19.3M | −$18.4M | −$8.7M | −$5.2M |
| Operating margin | −9,240.66% | −8,558.22% | −5,809.81% | −3,673.42% | — |
| EBITDA | −$22.0M | −$19.1M | −$18.2M | −$8.6M | — |
| EBITDA margin | −9,115.35% | −8,481.33% | −5,767.72% | −3,641.77% | — |
| Net income | −$23.8M | −$20.8M | −$29.9M | −$15.9M | −$251,633 |
| Net profit margin | −9,857.26% | −9,242.22% | −9,468.99% | −6,718.57% | — |
| Basic EPSper basic share | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| Diluted EPSper diluted share | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
Owners
Reported shareholders
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyClass A Common Stock | 18.75M | $0.40 | $7.50M | 21.70M |
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyWarrant Shares (Series A-2) · derivative | 18.75M | $0.00 | $0.00 | 18.75M |
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyWarrant Shares (Series A-1) · derivative | 11.25M | $0.00 | $0.00 | 11.25M |
| Feb 12, 2026Form 4 | Patel Mona ChetanDirector | BuyClass A Common Stock | 312.5K | $0.40 | $125.0K | 332.5K |
| Feb 12, 2026Form 4 | Patel Mona ChetanDirector | BuyWarrant (right to buy) · derivative | 312.5K | $0.00 | $0.00 | 312.5K |